


DCPLA-ME

Cat. No.:	HY-108599A		
CAS No.:	56687-67-3		
Molecular Formula:	C ₂₁ H ₃₈ O ₂		
Molecular Weight:	322.53		
Target:	PKC		
Pathway:	Epigenetics; TGF-beta/Smad		
Storage:	Pure form	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro	DMSO : 15.62 mg/mL (48.43 mM; Need ultrasonic)			
		Solvent Concentration	Mass	
			1 mg	5 mg
			10 mg	
	Preparing Stock Solutions	1 mM	3.1005 mL	15.5024 mL
	5 mM	0.6201 mL	3.1005 mL	6.2010 mL
	10 mM	0.3100 mL	1.5502 mL	3.1005 mL
Please refer to the solubility information to select the appropriate solvent.				
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 1.56 mg/mL (4.84 mM); Clear solution			
	2. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 1.56 mg/mL (4.84 mM); Clear solution			

BIOLOGICAL ACTIVITY

Description	DCPLA-ME, the methyl ester form of DCPLA, is a potent PKCε activator for use in the treatment of neurodegenerative diseases ^[1] .
IC ₅₀ & Target	PKCε

CUSTOMER VALIDATION

-
- Front Aging Neurosci. 1 March 2022.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Thomas J. Nelson, et al. Halogenated esters of cyclopropanated unsaturated fatty acids for use in the treatment of neurodegenerative diseases. WO2015058191A1.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA